DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R).

GUILDFORD, UNITED KINGDOM / ACCESS Newswire / May 28, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in ...

Japanese drugmaker Eisai (TYO: 4523) today announced that the in-house-discovered and developed orexin receptor antagonist ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...

BioArctic AB (BRCTF) reports a surge in revenue and profit, driven by strategic alliances and expanding market presence, while addressing future challenges.

According to the latest study from BCC Research, "Neurology Market: A BCC Research Overview" is estimated to increase from ...

The test will initially be available at about 50 American research institutes and hospitals that specialise in Alzheimer’s ...

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most ...

Micah McCartney is a reporter for Newsweek based in Taipei, Taiwan. He covers U.S.-China relations, East Asian and Southeast Asian security issues, and cross-strait ties between China and Taiwan.

A new narrative is gaining ground, stating that China is likely to invade Taiwan in the near future. The reasoning is straightforward: The Trump administration’s tariff war, and the potential ...

The United States and China recently announced a significant easing of tariffs, with both countries agreeing to reduce duties for a 90-day window. The financial press lauded the move. Stocks rallied.